Abstract
26,26,26,27,27,27-Hexafluoro-1α,25(OH)2 vitamin D3, a hexafluorinated analog of 1α,25(OH)2 vitamin D3, has been reported to be several times more potent than the parent compound with respect to some vitamin D actions. The reason for enhanced biological activity in the bones, kidneys, and small intestine appears to be related to F6-1α,25(OH)2 vitamin D3 metabolism to ST-232 (26,26,26,27,27,27-hexafluoro-1α,23S,25-trihydroxyvitamin D3), a bioactive 23S-hydroxylated form that is resistant to further metabolism. We compared the disposition and metabolism of [1β-3H]F6-1α,25(OH)2 vitamin D3 and [1β-3H]1α,25(OH)2 vitamin D3 in parathyroid glands of rats intravenously administered with labeled compounds at a dose of 10 μg/kg. In the [1β-3H]F6-1α,25(OH)2 vitamin D3-dosed group, radioactivity was highly detected in the kidneys, parathyroid glands, and the small intestine. The radioactivity in the parathyroid glands remained high until 48 h postdosing, with values of 2.5, 8.4, and 14.6 times higher at 6, 24, and 48 h postdosing than after dosing with [1β-3H] 1α,25(OH)2 vitamin D3. In the group given [1β-3H]F6-1α,25(OH)2 vitamin D3, the unchanged compound was mainly detected with a small amount of ST-232 at 6 h postdosing. At the 24- and 48-h time points, over half of the radioactivity was observed as ST-232, and additionally, ST-233, the 23-oxo form, accounted for a small amount at the 48-h time point. The present study demonstrated local retention of [1β-3H]F6-1α,25(OH)2 vitamin D3 and the bioactive metabolite ST-232 in parathyroid glands after intravenous administration. The findings may indicate one of the reasons for the higher potency of F6-1α,25(OH)2 vitamin D3 than 1α,25(OH)2 vitamin D3 in parathyroid.
Footnotes
-
↵1 Abbreviations used are: 1α,25(OH)2VD3, 1α,25-dihydroxyvitamin D3; PTH, parathyroid hormone; F6-1α,25(OH)2VD3, 26,26,26,27,27,27-hexafluoro-1α,25-dihydroxyvitamin D3; VDR, vitamin D receptor; ST-232 or 23S-hydroxy-F6-1α,25(OH)2VD3, 26,26,26,27,27,27-hexafluoro-1α,23S,25-trihydroxyvitamin D3; ST-233 or 23-oxo-F6-1α,(OH)VD3, 23oxo-26,26,26,27,27,27-hexafluoro-1α,25-dihydroxyvitamin D3; HPLC, high-performance liquid chromatography.
-
↵2 Present address: Sumitomo Chemical Deutschland GmbH, Dusseldorf, Germany.
- Received February 11, 2003.
- Accepted May 6, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|